Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR Serenity: Bempedoic acid in statin-intolerant patients
NCT02988115Phase 3Completed
- Sponsor
- Esperion Therapeutics
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Bempedoic Acid with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein Cholesterol at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02988115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988115.